Bempedoic acid

Lipid-lowering drug given a class I recommendation in the 2025 ESC/EAS guidelines; in Spain it is covered by therapeutic positioning report (IPT) 38/2022 (Nilemdo) and is also available in combination with ezetimibe (Nustendi).

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.